NCT06201663

Romiplostim in Chemotherapy-Induced Thrombocytopenia

Safety and Efficacy of Romiplostim in Chemotherapy-Induced Thrombocytopenia in Children and Adolescents With Solid Malignancy

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 1 Year – 18 Years
• Healthy volunteers: Not accepted

Summary

Prospective interventional randomized controlled trial to assess safety and efficacy of romiplostim in chemotherapy-induced thrombocytopenia in children and adolescents with solid malignancy

Detailed description

Chemotherapy-induced thrombocytopenia (CIT) frequently complicates cancer treatment causing delays in treatment and dose reduction for subsequent administration of cancer-directed treatment. Romiplostim is a potential agent that can improve platelet counts, allowing the resumption of chemotherapy, decreasing the need for platelet transfusions, and increasing the nadir platelet counts thus improving dose intensity.

Conditions

• Chemotherapy-induced Thrombocytopenia
• Solid Malignancy

Interventions

Type	Name	Description
DRUG	Romiplostim	Weekly subcutaneous injections

Timeline

• Start date: 2023-12-17
• Primary completion: 2025-05-01
• Completion: 2025-12-01
• First posted: 2024-01-11
• Last updated: 2024-01-11

Locations

1 site across 1 country: Egypt